“Dangling” Accelerated Approvals in Oncology

The FDA recently reevaluated accelerated approvals for 35 oncology indications for anti–programmed death ligand 1 antibodies, revealing that for 10 indications, the required trials did not end up confirming benefit and yet their marketing authorization continued.